Concert Pharmaceuticals, Inc. (CNCE) Misses Q2 EPS by 3c

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported Q2 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.3 million.

“The clinical and regulatory successes we have realized in the recent months are important to enabling our programs to advance into and through later stage clinical trials,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our proprietary drug candidates, including CTP-354 for spasticity, have the potential to achieve multiple development milestones in the second half of the year. Importantly, we plan to initiate a Phase 2 clinical trial for spasticity associated with spinal cord injury later this year. In addition, two of our drug candidates in development with collaborators have achieved recent clinical advancements which continue the strong momentum with these programs

For earnings history and earnings-related data on Concert Pharmaceuticals, Inc. (CNCE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Innovaro (INV) Misses Q2 EPS by 9c
• Dare Bioscience (DARE) Tops Q2 EPS by 11c